DiaMedica Therapeutics (DMAC) Return on Capital Employed (2019 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Return on Capital Employed came in at 71.36% in Q1 2026, up 533.0% year-on-year from 11.27% in Q1 2025, and down 12.19% quarter-over-quarter from 63.61% in Q4 2025.
DiaMedica Therapeutics (DMAC) Return on Capital Employed (2019 - 2026) Analysis & Trends
DiaMedica Therapeutics' Return on Capital Employed history runs 8 years deep, the most recent figure standing at 71.36% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 533.0% year-over-year to 71.36% in Q1 2026; TTM through Mar 2026 was 71.36%, a 533.0% increase from a year earlier, with the FY2025 full-year figure at 70.59%, down 1112.0% from the prior year.
- Return on Capital Employed declined to 71.36% in Q1 2026 per DMAC's latest filing, from 63.61% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 31.95% in Q1 2022 and bottomed at 101.35% in Q2 2025.
- The 5-year median for Return on Capital Employed is 44.82% (2024), against an average of 53.39%.
- Across the five-year window, Return on Capital Employed surged 3278 bps in 2022 and slumped 5653 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 41.73% in 2022, then climbed by 5 bps to 39.85% in 2023, then slumped by 52 bps to 60.58% in 2024, then slipped by 5 bps to 63.61% in 2025, then decreased by 12 bps to 71.36% in 2026.
- Per Business Quant, the three latest DMAC Return on Capital Employed figures stand at 71.36% (Q1 2026), 63.61% (Q4 2025), and 86.18% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | DiaMedica Therapeutics | 364.72 Mn | 364.72 Mn | - | -71.36% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -71.36% |
| Dec 31, 2025 | -63.61% |
| Sep 30, 2025 | -86.18% |
| Jun 30, 2025 | -101.35% |
| Mar 31, 2025 | -76.69% |
| Dec 31, 2024 | -60.58% |
| Sep 30, 2024 | -47.87% |
| Jun 30, 2024 | -44.82% |
| Mar 31, 2024 | -43.77% |
| Dec 31, 2023 | -39.85% |
| Sep 30, 2023 | -33.48% |
| Jun 30, 2023 | -39.29% |
| Mar 31, 2023 | -54.20% |
| Dec 31, 2022 | -41.73% |
| Sep 30, 2022 | -36.26% |
| Jun 30, 2022 | -34.60% |
| Mar 31, 2022 | -31.95% |
| Dec 31, 2021 | -29.94% |
| Sep 30, 2021 | -43.66% |
| Jun 30, 2021 | -67.38% |